home / stock / slno / slno news

SLNO News and Press, Soleno Therapeutics Inc.

Stock Information
Company Name: Soleno Therapeutics Inc.
Stock Symbol: SLNO
Market: NASDAQ
Website: soleno.life
Menu
SLNO SLNO Quote SLNO Short SLNO News SLNO Articles SLNO Message Board
Get SLNO Alerts

News, Short Squeeze, Breakout and More Instantly...
SLNO - Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome

REDWOOD CITY, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the submission of a New Drug Application (NDA) to...
SLNO - How to Take Advantage of moves in (SLNO)

2024-06-24 16:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

SLNO - Soleno Therapeutics to join Russell 3000 Index

2024-06-04 08:22:07 ET More on Soleno Therapeutics Soleno: Mid-2024 NDA Filing For PWS Treatment Is A Major Catalyst To Watch Soleno Therapeutics announces pricing of $138M public offering Read the full article on Seeking Alpha For further details see: So...

SLNO - Soleno Therapeutics Set to Join Russell 3000® Index

REDWOOD CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it is set to join the broad-market Russell 3...
SLNO - DWAS: High-Risk/High-Reward Small-Cap ETF

2024-06-03 10:10:04 ET Summary Invesco Dorsey Wright SmallCap Momentum ETF holds 199 small caps selected and weighted based on a proprietary momentum score. The DWAS ETF is overweight in industrials and healthcare, but well-diversified across holdings. Based on quality metrics...

SLNO - Where are the Opportunities in (SLNO)

2024-06-03 01:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

SLNO - Overweight Recommendation Issued On SLNO By Piper Sandler

2024-05-23 10:15:06 ET Piper Sandler analyst issues OVERWEIGHT recommendation for SLNO on May 23, 2024 08:40AM ET. The previous analyst recommendation was Overweight. SLNO was trading at $42.42 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
SLNO - Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024

REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that data from the randomized withdrawal period of...

SLNO - Soleno Therapeutics to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Office...

SLNO - Soleno Therapeutics Stands with the Prader-Willi Syndrome Community

REDWOOD CITY, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today launched a groundbreaking in...
Next 10